S&P 500   2,970.16 (0.00%)
DOW   26,845.69 (+0.11%)
QQQ   191.35 (+0.13%)
AAPL   237.21 (+0.42%)
FB   184.06 (-0.07%)
MSFT   139.90 (+0.16%)
AMZN   1,727.63 (-0.25%)
CGC   18.94 (-2.52%)
BABA   171.60 (-0.77%)
GE   8.75 (-0.57%)
TSLA   255.82 (+3.20%)
T   37.42 (-0.43%)
ACB   3.50 (-5.16%)
PRI   121.45 (-0.20%)
NFLX   283.39 (+0.16%)
DIS   129.74 (-0.22%)
S&P 500   2,970.16 (0.00%)
DOW   26,845.69 (+0.11%)
QQQ   191.35 (+0.13%)
AAPL   237.21 (+0.42%)
FB   184.06 (-0.07%)
MSFT   139.90 (+0.16%)
AMZN   1,727.63 (-0.25%)
CGC   18.94 (-2.52%)
BABA   171.60 (-0.77%)
GE   8.75 (-0.57%)
TSLA   255.82 (+3.20%)
T   37.42 (-0.43%)
ACB   3.50 (-5.16%)
PRI   121.45 (-0.20%)
NFLX   283.39 (+0.16%)
DIS   129.74 (-0.22%)
Log in

IsoRay Stock Price, News & Analysis (NYSEAMERICAN:ISR)

$0.32
0.00 (0.00 %)
(As of 10/14/2019 11:50 AM ET)
Today's Range
$0.32
Now: $0.32
$0.33
50-Day Range
$0.31
MA: $0.34
$0.40
52-Week Range
$0.27
Now: $0.32
$0.52
Volume13,601 shs
Average Volume157,196 shs
Market Capitalization$21.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ISR
Previous SymbolNYSEMKT:ISR
CUSIPN/A
Phone+1-509-3751202

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees38
Market Cap$21.36 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.


IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions

What is IsoRay's stock symbol?

IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NYSEAMERICAN:ISR) posted its earnings results on Tuesday, September, 24th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). The healthcare company earned $1.92 million during the quarter, compared to analyst estimates of $1.82 million. View IsoRay's Earnings History.

When is IsoRay's next earnings date?

IsoRay is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for IsoRay.

What price target have analysts set for ISR?

3 equities research analysts have issued 1 year price objectives for IsoRay's stock. Their predictions range from $0.70 to $0.70. On average, they expect IsoRay's stock price to reach $0.70 in the next year. This suggests a possible upside of 120.7% from the stock's current price. View Analyst Price Targets for IsoRay.

What is the consensus analysts' recommendation for IsoRay?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IsoRay.

What are Wall Street analysts saying about IsoRay stock?

Here are some recent quotes from research analysts about IsoRay stock:
  • 1. According to Zacks Investment Research, "IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. " (9/28/2019)
  • 2. HC Wainwright analysts commented, "We derive a 12-month price target of $0.70 per share based on an NPV analysis of projected product revenues through FY2030. We assume a 12.7% discount rate and a 3% terminal growth rate. We derive an NPV of $85M and add in cash and cash equivalents of $6M to arrive at a 12-month price target of $0.71, which we round to $0.70." (5/13/2019)
  • 3. Maxim Group analysts commented, "IsoRay reported the September quarter (FYE: June) with Cs-131 revenue of $1.56M, down 2.5% sequentially, and flat with the Dec and Mar quarters. The company ended the period with $9.2M in cash, including net proceeds of $8.25M from a July equity financing. Our fundamental view of Cs-131 is as a superior isotope for radio-therapy remains intact though IsoRay continues to struggle to drive revenue growth. It’s still early stage for Blu-Build and the question is can GammaTile be the answer? At this point it’s too early to tell and we see only incremental revenue growth. As such, we opt to step down to a Hold rating, from Buy, remove our price target." (11/9/2018)

Has IsoRay been receiving favorable news coverage?

News coverage about ISR stock has trended negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IsoRay earned a news impact score of -2.6 on InfoTrie's scale. They also gave news coverage about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for IsoRay.

Who are some of IsoRay's key competitors?

What other stocks do shareholders of IsoRay own?

Who are IsoRay's key executives?

IsoRay's management team includes the folowing people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 57)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 48)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 53)
  • Mr. Jonathan R. Hunt, Co-Principal Financial Officer (Age 52)
  • Mr. Mark J. Austin CPA, Controller & Co-Principal Financial Officer (Age 32)

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.32.

How big of a company is IsoRay?

IsoRay has a market capitalization of $21.36 million. IsoRay employs 38 workers across the globe.View Additional Information About IsoRay.

What is IsoRay's official website?

The official website for IsoRay is http://isoray.com/.

How can I contact IsoRay?

IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.


MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel